2 D) tended to increase in patients treated with ICI plus platinum and paclitaxel compared to those treated with platinum and paclitaxel, although they did not reach statistical significance.
← all excerpts
The outcome of advanced and recurrent cervical cancer patients treated with first-line platinum and paclitaxel with or without indication for immune checkpoint inhibitors: the comparative study.
1
—
—